Reinduction of Cell Differentiation and 131 I Uptake in a Poorly Differentiated Thyroid Tumor in Response to the Reverse Transcriptase (RT) Inhibitor Nevirapine
- 1 April 2007
- journal article
- research article
- Published by SAGE Publications in Cancer Biotherapy and Radiopharmaceuticals
- Vol. 22 (2) , 289-295
Abstract
Our recent findings have shown that the reverse transcriptase (RT) inhibitors, nevirapine and efavirenz, used for 10 years in human immunodeficiency virus (HIV) disease, act as cytostatic and differentiating agents by modulating gene expression in several human tumor cell models. In dedifferentiated thyroid cancer, they reestablish thyroid-stimulating hormone (TSH) signaling, Na/I symporter (NIS), thyroglobulin peroxydase (TPO) expression, and even radioiodine uptake (RIU). In this paper, we describe the case of a 76-year-old woman who was affected by thyroid papillary carcinoma and who underwent a total thyroidectomy and a debulking of the right laterocervical region for lymph-node metastases, vessel infiltration, and neoplastic thrombosis of the internal jugular vein, followed by 3 radioiodine treatments. At restaging, a computed tomography scan revealed that distant metastases were mostly not taking up the radioiodine at the 131I whole-body scan (WBS). An analysis of tumor cells obtained by fine-needle aspiration biopsy of a right laterocervical lymph-node revealed cell anisokaryosis, nuclear pleomorphism, and scanty colloid, as well as the undetectable expression of thyroglobulin and NIS proteins. After starting a nevirapine treatment (NT), higher thyroglobulin levels were observed and some metastases exhibited a significant increase in radioiodine uptake, which led us to again treat the patient with 131I. Five (5) months later, the 131I-WBS revealed the disappearance of RIU in some metastases and its significant reduction in other lesions, with a parallel drop in serum thyroglobulin. No new metastatic lesion was revealed by rh-TSH-stimulated 131IWBS and 18F-flourodeoxyglucose positron emission tomography scan. Cells obtained from the right laterocervical lymph-node 2 months after NT exhibited a reduced nuclear pleomorphism, an increase in colloid production, and a significant upregulation of thyroglobulin and NIS protein expression. This first in vivo molecular and morphologic evidence of cell differentiation in human cancer and low toxicity of nevirapine strongly encourage its use in dedifferentiated thyroid cancer treatment.Keywords
This publication has 14 references indexed in Scilit:
- Enhanced Radioiodine Uptake in a Patient With Poorly Differentiated Papillary Thyroid Cancer After Treatment With RosiglitazoneClinical Nuclear Medicine, 2006
- Troglitazone, the Peroxisome Proliferator-Activated Receptor-γ Agonist, Induces Antiproliferation and Redifferentiation in Human Thyroid Cancer Cell LinesThyroid®, 2005
- Valproic Acid Induces Apoptosis and Cell Cycle Arrest in Poorly Differentiated Thyroid Cancer CellsThe Journal of Clinical Endocrinology & Metabolism, 2005
- Redifferentiation Therapy in Advanced Thyroid CancerCurrent Drug Target - Immune, Endocrine & Metabolic Disorders, 2004
- Histone Deacetylase Inhibitors Restore Radioiodide Uptake and Retention in Poorly Differentiated and Anaplastic Thyroid Cancer Cells by Expression of the Sodium/Iodide Symporter Thyroperoxidase and ThyroglobulinEndocrinology, 2004
- Lovastatin, a 3-Hydroxy-3-methylglutaryl Coenzyme A Reductase Inhibitor, Induces Apoptosis and Differentiation in Human Anaplastic Thyroid Carcinoma CellsThe Journal of Clinical Endocrinology & Metabolism, 2003
- Exposure of normal and transformed cells to nevirapine, a reverse transcriptase inhibitor, reduces cell growth and promotes differentiationOncogene, 2003
- Retinoic acid for redifferentiation of thyroid cancer--does it hold its promise?European Journal of Endocrinology, 2003
- Structural mechanisms of drug resistance for mutations at codons 181 and 188 in HIV-1 reverse transcriptase and the improved resilience of second generation non-nucleoside inhibitors 1 1Edited by J. KarnJournal of Molecular Biology, 2001
- Retinoic Acid Increases Sodium/Iodide Symporter mRNA Levels in Human Thyroid Cancer Cell Lines and Suppresses Expression of Functional Symporter in Nontransformed FRTL-5 Rat Thyroid CellsBiochemical and Biophysical Research Communications, 1997